NCT04835948View on ClinicalTrials.gov

Efficacy of Single Dose Anti-thymocyte Globulin in the Modulation of T Lymphocytes in Kidney Transplantation

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

October 20, 2018

Primary Completion Date

March 31, 2020

Study Completion Date

April 13, 2021

Conditions
Kidney Transplant; ComplicationsImmunosuppression
Interventions
DRUG

single dose of Anti-thymocyte globulin

Used anti-thymocyte globulin (ATG) in a single dose of 3 mg/kg for immunosuppression induction in the immediate postoperative period

Trial Locations (1)

Unknown

Hospital de Clínicas de Porto Alegre, Porto Alegre

All Listed Sponsors
lead

Hospital de Clinicas de Porto Alegre

OTHER

NCT04835948 - Efficacy of Single Dose Anti-thymocyte Globulin in the Modulation of T Lymphocytes in Kidney Transplantation | Biotech Hunter | Biotech Hunter